Literature DB >> 34270783

Antibiotic overuse in older patients: an important clinical reminder of pseudomembranous colitis.

C M H Pinxt1,2,3,4, R M M Bogie1,2,3,4, N M J Hanssen1,2,3,4, B Spaetgens1,2,3,4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34270783      PMCID: PMC8686195          DOI: 10.1093/qjmed/hcab198

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


× No keyword cloud information.
A 79-year-old woman with a history of diverticulosis presented to the emergency department with abdominal pain, diarrhea and fever (38.6°C) since 3 days. Diverticulitis was ruled out with an abdominal CT scan, but diffuse circumferential wall thickening of the entire colon and rectosigmoid was observed (Figure 1A). Since the patient received antibiotics (amoxicillin/clavulanate) during a recent COVID-19 infection, Clostridium difficile infection (CDI) was considered. Colonoscopy showed characteristic white–yellow pseudomembranous plaques (Figure 1B) and also a stool sample for C. difficile toxin turned out positive. The CDI was treated with vancomycin and patient recovered swiftly.
Figure 1.

Images of the patient with (A) an abdominal CT scan showing diffuse circumferential wall thickening (consistent with submucosal edema) of the entire colon and (B) a colonoscopy image showing the characteristic white–yellow, elevated plaques converging to pseudomembranes on the mucosa.

Images of the patient with (A) an abdominal CT scan showing diffuse circumferential wall thickening (consistent with submucosal edema) of the entire colon and (B) a colonoscopy image showing the characteristic white–yellow, elevated plaques converging to pseudomembranes on the mucosa. The aging process itself, malnutrition and antibiotic (over)use may cause a reduction in gut microbial diversity that increases CDI susceptibility., In addition, an emerging body of studies reveal widespread overuse of antibiotics in patients with COVID-19, entailing an increased risk of adverse events, such as CDI., Therefore, this case underlines that perceived benefits of antibiotic prescription, especially in (frail) older patients, may be offset by greater harm by microbial perturbation. Since gut microbial perturbation is also linked to a range of chronic conditions, this is an area of research that may be on the cusp of altering clinical practice. Conflict of interest. None declared.
  5 in total

1.  Risk factors for Clostridium difficile colonisation and toxin production.

Authors:  John M Starr; Heather Martin; Jodie McCoubrey; Gavin Gibson; Ian R Poxton
Journal:  Age Ageing       Date:  2003-11       Impact factor: 10.668

Review 2.  Older Is Not Wiser, Immunologically Speaking: Effect of Aging on Host Response to Clostridium difficile Infections.

Authors:  Jae Hyun Shin; Kevin P High; Cirle A Warren
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2016-01-25       Impact factor: 6.053

3.  Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID.

Authors:  Jorge Calderón-Parra; Antonio Muiño-Miguez; Alejandro D Bendala-Estrada; Antonio Ramos-Martínez; Elena Muñez-Rubio; Eduardo Fernández Carracedo; Javier Tejada Montes; Manuel Rubio-Rivas; Francisco Arnalich-Fernandez; Jose Luis Beato Pérez; Jose Miguel García Bruñén; Esther Del Corral Beamonte; Paula Maria Pesqueira Fontan; Maria Del Mar Carmona; Rosa Fernández-Madera Martínez; Andrés González García; Cristina Salazar Mosteiro; Carlota Tuñón de Almeida; Julio González Moraleja; Francesco Deodati; María Dolores Martín Escalante; María Luisa Asensio Tomás; Ricardo Gómez Huelgas; José Manuel Casas Rojo; Jesús Millán Núñez-Cortés
Journal:  PLoS One       Date:  2021-05-11       Impact factor: 3.240

Review 4.  Fecal microbiota transplantation in human metabolic diseases: From a murky past to a bright future?

Authors:  Nordin M J Hanssen; Willem M de Vos; Max Nieuwdorp
Journal:  Cell Metab       Date:  2021-06-01       Impact factor: 27.287

5.  Antibiotic use in patients with COVID-19: a 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey.

Authors:  Bojana Beović; May Doušak; João Ferreira-Coimbra; Kristina Nadrah; Francesca Rubulotta; Mirko Belliato; Joana Berger-Estilita; Folusakin Ayoade; Jordi Rello; Hakan Erdem
Journal:  J Antimicrob Chemother       Date:  2020-11-01       Impact factor: 5.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.